8-K: Sanuwave Achieves Record 2025 Revenues, Strong Growth

Sanuwave Health, Inc. announced record revenues for both the fourth quarter and full year 2025, driven by strong UltraMIST system and consumables sales.

Summary

• Q4 2025 revenues reached an all-time quarterly record of $13.4 million, marking a 29.7% increase from Q4 2024.
• Full year 2025 revenues achieved an all-time annual record of $44.1 million, up 35.0% from full year 2024.
• Q4 2025 gross margin was 74.7%, or 78.3% when adjusted for a $486 thousand write-off of PACE inventory.
• Full year 2025 gross margin improved to 77.1% from 75.2% in 2024.
• GAAP Operating Income for Q4 2025 was $2.0 million, and for the full year 2025, it was $4.9 million, an increase of $1.1 million from 2024.
• Net income for Q4 2025 was $7.7 million, a significant improvement from a $13.3 million net loss in Q4 2024, primarily due to changes in the fair value of derivative liabilities.
• Full year 2025 net income was $11.8 million, compared to a $33.1 million net loss in 2024, driven by derivative liabilities, other income, and increased operating profit.
• Adjusted EBITDA for Q4 2025 was $4.8 million, an improvement of $1.1 million from Q4 2024, and for the full year 2025, it was $13.6 million, an improvement of $6.5 million from 2024.
• UltraMIST systems and consumables were the primary revenue drivers, accounting for nearly 100% of overall revenues.
• The Company sold 255 UltraMIST systems in Q4 2025 (up from 135 in Q4 2024) and 624 systems in full year 2025 (up from 374 in 2024).
• UltraMIST consumables revenue increased by 10.6% to $6.5 million in Q4 2025 and by 27.4% to $25.5 million for the full year 2025.
• Management acknowledges navigating challenging industry conditions, including CMS reimbursement cuts to skin substitutes and an aggressive CMS audit environment in the wound care space.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report, demonstrating record revenues, significant profitability improvements, and effective navigation of challenging industry dynamics, despite some short-term headwinds.

Positives

• Achieved all-time record quarterly revenue of $13.4 million in Q4 2025, representing a 29.7% year-over-year increase.
• Achieved all-time record annual revenue of $44.1 million in full year 2025, a 35.0% increase from the prior year.
• Full year gross margin improved to 77.1% in 2025 from 75.2% in 2024.
• Operating income for full year 2025 increased by $1.1 million to $4.9 million, reflecting efforts to drive profitable growth.
• Reported substantial net income of $7.7 million in Q4 2025 and $11.8 million for full year 2025, a significant turnaround from net losses in the prior year periods.
• Adjusted EBITDA showed strong growth, increasing by $1.1 million to $4.8 million in Q4 2025 and by $6.5 million to $13.6 million for full year 2025.
• Strong sales growth of UltraMIST systems, with 255 units sold in Q4 2025 (up from 135 in Q4 2024) and 624 units in FY2025 (up from 374 in FY2024).
• Increased interest from large, skilled distributors and resellers in UltraMIST, indicating potential for expanded market reach.
• Management views the CMS focus on medical necessity and value for money in wound care as a long-term beneficial trend for the Company.

Negatives

• Q4 2025 gross margin decreased to 74.7% from 77.9% in Q4 2024, primarily due to a $486 thousand write-off of PACE inventory associated with product line sunsetting.
• Q4 2025 operating income remained flat at $2.0 million compared to Q4 2024, impacted by the inventory write-off and a $479 thousand sales tax expense.
• The wound care space is experiencing significant disruption due to CMS reimbursement cuts to skin substitutes and an intensified CMS audit environment.
• Large numbers of mobile wound care providers are exiting the market or reducing staff in response to new pricing and aggressive audits.
• Lower consumables sales in Q4 2025 were observed due to some customers going out of business and others reducing patient volumes.

Risks

• Regulatory oversight, as mentioned in forward-looking statements.
• Ability to manage capital resources effectively.
• Competition within the wound care market.
• Ongoing impact of CMS reimbursement cuts to skin substitutes.
• Intensification of the CMS audit environment, potentially affecting customer base and sales volumes.
• Choppy transition period in the wound care market due to changing dynamics and provider exits.

Future Outlook

The Company forecasts Q1 2026 revenue between $9.6 million and $10.3 million, representing a 3-10% increase from Q1 2025. For the full year 2026, revenue guidance is set at $51.0 million to $55.0 million, indicating a projected growth of 16-25% compared to full year 2025 revenue.

Management Comments

• "We're pleased to be, once more, announcing an all-time record quarter for Sanuwave on both revenues and adjusted EBITDA, especially during such challenging times in the wound care space." CEO Morgan Frank.
• "The effects of the CMS reimbursement cut to skin substitutes and an intensification of the CMS audit environment have been dramatically reshaping a number of sectors of wound care, particularly mobile care." CEO Morgan Frank.
• "Q4 2025 saw the first major reactions to the new pricing with large numbers of mobile wound care providers exiting the space and/or cutting staff." CEO Morgan Frank.
• "It seems very much to be a one tide going out while another tide is coming in sort of moment for the space and, while such transitions are inevitably choppy, it seems like a lot of this change will ultimately flow our way." CEO Morgan Frank.
• "UltraMIST remains a potent solution ready made for the work and business flow of our customers and the needs of those they care for." CEO Morgan Frank.
• "CMS appears to have made a determination to focus heavily on medical necessity and value for money in the wound care space and while this has created a bit of a stutter step in the short run, we see it as a trend that should be long term beneficial to us." CEO Morgan Frank.

Industry Context

StockSavvy.ai notes that Sanuwave is navigating a significant upheaval in the wound care industry, characterized by CMS reimbursement cuts to skin substitutes and an intensified audit environment. This has led to a "choppy" transition, with some mobile wound care providers exiting the market while new entrants and existing companies are adapting, potentially creating opportunities for Sanuwave's UltraMIST product, which management believes aligns with CMS's focus on medical necessity and value.

Stakeholder Impact

• Shareholders: Positive impact due to record revenues, improved profitability, and positive future guidance, potentially leading to increased share value.
• Employees: Continued growth and market adaptation may provide job security and opportunities, though some market shifts could impact certain roles.
• Customers: UltraMIST remains a "potent solution" for wound care needs, but some customers (mobile wound care providers) are exiting the market due to CMS changes.
• Suppliers: Increased demand for UltraMIST systems and consumables suggests continued business for suppliers.
• Creditors: Improved financial health, including positive net income and Adjusted EBITDA, strengthens the company's ability to service its debt obligations.

Next Steps

• Business update via conference call on March 27, 2026, at 8:30 a.m. EST.
• Conference call replay available through April 10, 2026.

Key Dates

Recommendation

The company delivered record revenues and a significant turnaround from net losses to substantial net income and Adjusted EBITDA, exceeding prior year performance and meeting or exceeding guidance. Despite industry headwinds from CMS changes, management has a clear strategy, including leveraging new distribution channels, and projects continued strong revenue growth for 2026. This indicates robust operational execution and a favorable long-term outlook for investors.

Keywords

Sanuwave Health, SNWV, wound care, UltraMIST, medical devices, financial results, revenue growth, EBITDA, SEC filing, Q4 2025, full year 2025, CMS reimbursement, healthcare